Zobrazeno 1 - 10
of 28
pro vyhledávání: '"BOGLÁRKA, SOÓS"'
Autor:
Diána Simon, Dorottya Kacsándi, Anita Pusztai, Boglárka Soós, Edit Végh, György Kerekes, Monika Bodoki, Szilvia Szamosi, Gabriella Szűcs, Zoltán Prohászka, Péter Németh, Tímea Berki, Zoltán Szekanecz
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 6, p 3429 (2024)
Cardiovascular (CV) morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Natural autoantibodies (nAAb) are involved in innate immunity, as well as autoimmunity, inflammation, and atherosclerosis
Externí odkaz:
https://doaj.org/article/71f2a4f53dee47f8860debc5ee7c805e
Autor:
Dorottya Kacsándi, Miklós Fagyas, Ágnes Horváth, Edit Végh, Anita Pusztai, Monika Czókolyová, Boglárka Soós, Attila Ádám Szabó, Attila Hamar, Zsófia Pethő, Nóra Bodnár, György Kerekes, Katalin Hodosi, Szilvia Szamosi, Gabriella Szűcs, Zoltán Papp, Zoltán Szekanecz
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionThe Renin-Angiotensin-Aldosterone system (RAAS) has been implicated in the regulation of the cardiovascular system and linked to rheumatoid arthritis (RA). Little information has become available on the effects of Janus kinase (JAK) inhib
Externí odkaz:
https://doaj.org/article/f41fec7a849149948aedbbc135bef895
Autor:
Boglárka Soós, Attila Hamar, Anita Pusztai, Monika Czókolyová, Edit Végh, Szilvia Szamosi, Zsófia Pethő, Katalin Gulyás, György Kerekes, Sándor Szántó, Gabriella Szűcs, Uwe Christians, Jelena Klawitter, Tamás Seres, Zoltán Szekanecz
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionRheumatoid arthritis (RA) has been associated with changes in lipid, arginine and NO metabolism with increased cardiovascular (CV) risk. The aim of this study is to evaluate the effect of tofacitinib, a Janus kinase (JAK) inhibitor, on ar
Externí odkaz:
https://doaj.org/article/a6061826902b48d89056abe612f96e15
Autor:
Ildikó Tar, Éva Csősz, Edit Végh, Karin Lundberg, Nastya Kharlamova, Boglárka Soós, Zoltán Szekanecz, Ildikó Márton
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Periodontal disease (PD) can be an important precipitating factor in the production of citrullinated proteins. Its importance is emphasized, but it is not the only way to produce citrullinated proteins. The aim of the current study was to de
Externí odkaz:
https://doaj.org/article/d0cb1d8048684778a84d973d065145b9
Autor:
Boglárka Soós, Miklós Fagyas, Ágnes Horváth, Edit Végh, Anita Pusztai, Monika Czókolyová, Alexandra Csongrádi, Attila Hamar, Zsófia Pethő, Nóra Bodnár, György Kerekes, Katalin Hodosi, Éva Szekanecz, Szilvia Szamosi, Sándor Szántó, Gabriella Szűcs, Zoltán Papp, Zoltán Szekanecz
Publikováno v:
Frontiers in Medicine, Vol 8 (2022)
IntroductionAngiotensin-converting enzyme (ACE) and ACE2 have been implicated in the regulation of vascular physiology. Elevated synovial and decreased or normal ACE or ACE2 levels have been found in rheumatoid arthritis (RA). Very little is known ab
Externí odkaz:
https://doaj.org/article/9be3049328d844bfb17fcc4b90d78fb4
Autor:
Monika Czókolyová, Attila Hamar, Anita Pusztai, Gábor Tajti, Edit Végh, Zsófia Pethő, Nóra Bodnár, Ágnes Horváth, Boglárka Soós, Szilvia Szamosi, Anita Szentpéteri, Ildikó Seres, Mariann Harangi, György Paragh, György Kerekes, Levente Bodoki, Andrea Domján, Katalin Hodosi, Tamás Seres, György Panyi, Zoltán Szekanecz, Gabriella Szűcs
Publikováno v:
Biomolecules, Vol 12, Iss 10, p 1483 (2022)
Background: Cardiovascular (CV) morbidity, mortality and metabolic syndrome are associated with rheumatoid arthritis (RA). A recent trial has suggested increased risk of major CV events (MACE) upon the Janus kinase (JAK) inhibitor tofacitinib compare
Externí odkaz:
https://doaj.org/article/1bf883c526d04d30b1814f3d8a0c694f
Publikováno v:
Immunology Quaterly / Immunológia Szemle; apr2024, Vol. 16 Issue 1, p6-16, 11p
Autor:
Ildikó Tar, Edit Végh, Renáta Martos, Boglárka Soós, Dorottya Kacsándi, Ildikó Márton, Zoltán Szekanecz
Introduction: Peridontitis has been associated with inflammatory rheumatic diseases. Objectives: We evaluated oral mucosal, periodontal, and periapical dental condition of 24 arthritis patients at baseline and after six months of biological therapy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0872b36295766ed718088a0d49c76f00
https://doi.org/10.21203/rs.3.rs-2728661/v1
https://doi.org/10.21203/rs.3.rs-2728661/v1
Autor:
Szűcs, Monika Czókolyová, Attila Hamar, Anita Pusztai, Gábor Tajti, Edit Végh, Zsófia Pethő, Nóra Bodnár, Ágnes Horváth, Boglárka Soós, Szilvia Szamosi, Anita Szentpéteri, Ildikó Seres, Mariann Harangi, György Paragh, György Kerekes, Levente Bodoki, Andrea Domján, Katalin Hodosi, Tamás Seres, György Panyi, Zoltán Szekanecz, Gabriella
Publikováno v:
Biomolecules; Volume 12; Issue 10; Pages: 1483
Background: Cardiovascular (CV) morbidity, mortality and metabolic syndrome are associated with rheumatoid arthritis (RA). A recent trial has suggested increased risk of major CV events (MACE) upon the Janus kinase (JAK) inhibitor tofacitinib compare
Autor:
Boglárka Soós, Ágnes Szentpétery, Hennie G. Raterman, Willem F. Lems, Harjit P. Bhattoa, Zoltán Szekanecz
Publikováno v:
Soós, B, Szentpétery, Á, Raterman, H G, Lems, W F, Bhattoa, H P & Szekanecz, Z 2022, ' Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases ', Nature Reviews Rheumatology, vol. 18, no. 5, pp. 249-257 . https://doi.org/10.1038/s41584-022-00764-w
Generalized bone loss (osteoporosis) and fragility fractures can occur in rheumatic and musculoskeletal diseases including rheumatoid arthritis and spondyloarthritis (SpA; including ankylosing spondylitis and psoriatic arthritis). In addition, rheuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d87d0ff9040edbe68bfddeff290c8f07
https://research.vumc.nl/en/publications/6e360026-9560-43a5-800c-ba9fe628011f
https://research.vumc.nl/en/publications/6e360026-9560-43a5-800c-ba9fe628011f